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Available online 19 April 2018Background: In patients with angina undergoing invasive management, no obstructive coronary artery disease
(NOCAD) is a common finding, and angina may persist following percutaneous coronary intervention (PCI).
Coronary microvascular dysfunction may be relevant. We aimed to assess the proportion of patients presenting
with suspected CAD who had coronary microvascular dysfunction.
Methods: Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease 2 (CE-MARC 2) was a
prospective multicenter randomised controlled trial of functional imaging versus guideline-based management
in patients with suspected CAD. Invasive coronary angiography was protocol-directed. Fractional flow reserve
(FFR) and parameters of microvascular function (coronary flow reserve (CFR), index of microcirculatory
resistance (IMR), resistance reserve ratio (RRR)) were measured in major epicardial coronary arteries with
≥40–≤90% diameter stenosis. An FFR value ≤0.80 indicated the presence of obstructive CAD.
Results: 267/1202 (22.2%) patients underwent angiography and 81 (30%) patients had FFR measured. 63 (78%)
of these patients had microvascular function assessed in 85 arteries (mean age 58.5 ± 8.2 years; 47 (75%)
male). 25/63 (40%) patients had NOCAD, and of these, 17 (68%) had an abnormality ≥1 parameter of microvas-
cular function (abnormal IMR (≥25), abnormal CFR (b2.0), and abnormal RRR (b2.0) occurred in 10 (40%), 12
(48%), and 11 (44%), respectively). 38/63 (60%) patients had obstructive epicardial CAD. Of these patients, 15/
38 (39%), 20/38 (53%), and 12/38 (32%) had an abnormal IMR, CFR and RRR, respectively.
Conclusions: Coronary microvascular dysfunction is common in patients with angina. Invasive assessment of
microvascular function may be informative and relevant for decision-making in patients with both NOCAD and
obstructive epicardial CAD.
Clinical trial registration: ClinicalTrials.gov Identifier: NCT01664858
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
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Ischaemic heart disease (IHD) persists as the leading global cause
of death standardised by age and sex [1]. A considerable proportion of
patients with angina have non-flow limiting (non-obstructive) epicar-
dial coronary artery disease (CAD) [2]. Angina may persist in patients
following technically successful percutaneous coronary intervention
(PCI) as reported by the Percutaneous Coronary Intervention in Stable
Angina (ORBITA) trial investigators [3]. Although several factors may
be relevant, ‘microvascular angina’ is an explanation in some patientsthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cal management is supported by contemporary practice guidelines [10].
Given the challenges in diagnosing and treatingmicrovascular angina in
clinical practice, it is a condition of unmet clinical need [11].
Advances in interventional diagnostic techniques [12,13] enable
new insights into coronary microvascular function in patients with
stable CAD [14]. Invasive diagnostic tests identify abnormalities in
vasodilator capacity (coronary flow reserve, CFR; resistance reserve
ratio, RRR) and microvascular resistance (index of microcirculatory
resistance, IMR) in patientswith obstructive or no obstructive epicardial
CAD (NOCAD). The availability of these invasive tests provides a refer-
ence dataset for comparison against non-invasive functional testing.
We aimed to assess the prevalence of coronary microvascular
dysfunction in patients with suspected stable IHD who had been
referred for invasive coronary angiography in the Clinical Evaluation
of Magnetic Resonance Imaging in Coronary Heart Disease 2 (CE-
MARC 2) clinical trial (ClinicalTrials.gov Identifier: NCT01664858)
[15]. CE-MARC 2 was a UK prospective multicentre three-arm parallel
group, randomised controlled trial of routine functional imaging versus
guideline-based management in patients presenting with suspected
angina. In this pre-specified sub-study, the primary aim was to assess
the proportion of patients with abnormal coronary microvascular
function, in those with both NOCAD and obstructive epicardial CAD.
Secondary aimswere to assess the associations between clinical charac-
teristics and abnormal coronary microvascular function, and between
non-invasive diagnostic tests for stable IHD and abnormalities in
coronary microvascular function.
2. Methods
2.1. Study population
CE-MARC 2 randomised 1202 patients (2:2:1) to 3.0 Tesla stress perfusion cardiovas-
cular magnetic resonance (CMR), myocardial perfusion scintigraphy (MPS) (according to
American College of Cardiology/American Heart Association appropriate-use criteria), or
to management based on the pre-test probability of CAD (10–29%: CT (computed tomog-
raphy) calcium scoring± CTCA (CT coronary angiography); 30–60%: MPS; 61–90%: inva-
sive coronary angiography) [16]. The UK National Institute for Health and Care Excellence
(NICE) clinical practice guidelines recommendnon-invasive functional testing for patients
for the assessment of angina in patients with confirmed CAD [17]. Patients age ≥30 years
with known or suspected angina, a pre-test likelihood of epicardial CAD 10–90%, and
who were deemed suitable for myocardial revascularisation were enrolled. Key exclusion
criteria included non-anginal chest pain, a normalMPS or CTCA result b2 years previously,
priormyocardial infarction, prior coronary revascularisation, and contraindication toMPS,
CMR, or CTCA. Following enrolment, patients were referred for invasive coronary angiog-
raphy following either i) positive CMR,MPS, or CTCA, ii) patients with a pre-test probabil-
ity of CAD 61–90% randomised into the NICE-guided strategy, iii) inconclusive CMR, MPS,
or CTCA, iv) clinician decision.
Following invasive angiography, coronary arteries ≥2.5 mmwith a visually-assessed
≥40–≤90% diameter stenosis underwent protocol-directed fractional flow reserve (FFR)
measurement to assess for flow-limiting epicardial CAD. The invasive coronary physiology
recordings were prospectively collected from the 6 study sites for analysis in the Glasgow
Coronary Physiology Core Laboratory. Recordings were analysed off-line using
RADIVIEW™ (St. Jude Medical, St. Paul, MN) by 2 experienced observers (D.C. and C.B.).
The Gensini score was calculated to quantify the epicardial CAD burden [18].
2.2. Coronary physiology protocol
Coronary physiology measurements were performed with a dual coronary pressure-
and temperature-sensitive guide wire (Certus™, St. Jude Medical, St. Paul, MN). Arteries
undergoing FFR measurement also had parameters of microvascular function assessed.
The coronary guidewire was calibrated outside the body, equalised with aortic pressure
at the coronary guide catheter ostium, and advanced to the distal third of the epicardial
coronary artery undergoing interrogation. Resting thermodilution was performed using
3 intracoronary boluses of room temperature 0.9% saline. Maximal hyperaemia was then
induced by an intracoronary bolus of 200 μg nitrate and a 3-min peripheral intravenous
adenosine infusion (140 μg/kg/min), and hyperaemic thermodilution was performed
using 3 intracoronary boluses of room temperature 0.9% saline. Mean aortic and distal
coronary pressures were recorded during rest and maximal hyperaemia, and the mean
resting and hyperaemic transit times derived.
The invasive measurements of epicardial andmicrovascular function were: 1. FFR de-
scribes the functional significance of an epicardial stenosis: FFR= distal coronary pressure
(Pd)/aortic pressure (Pa), at maximal hyperaemia [19]; 2. CFR describes the vasodilatory
capacity of the epicardial andmicrovascular coronary compartments: CFR=mean restingtransit time/meanhyperaemic transit time [20]; 3. IMR is ameasure of coronarymicrovas-
cular resistance: IMR = Pd × mean transit time, at maximal hyperaemia [21]. IMR was
uncorrected for coronary wedge pressure [22]; 4. Resistance reserve ratio (RRR) is a mea-
sure of the vasodilatory capacity of the microcirculation: RRR= RI/IMR, (RI = baseline
resistance index, calculated as: resting Pd ×mean resting transit time [23].
2.3. Non-invasive ischaemia imaging
The CMR and MPS protocols used in the CE-MARC 2 trial have been previously
described [15]. Non-invasive ischaemia tests that were reported as demonstrating
‘significant ischaemia’ or ‘inconclusive’ triggered referral for invasive coronary angiogra-
phy. Significant ischaemia was defined as: i) CMR criteria: any segment with transmural
ischaemia, ischaemia N60° (basal/mid) or N90° (apical) of left ventricular circumference,
or ischaemia in ≥2 adjacent segments; ii)MPS criteria: summed stress score ≥4 in patients.
2.4. Definitions of obstructive epicardial coronary artery disease and microvascular
dysfunction
The cohort was dichotomised into obstructive CAD and NOCAD on a per-patient and
per-vessel basis. For the per-patient analysis, obstructive CAD was defined as any epicar-
dial coronary stenosis with FFR ≤0.80, or if FFR was not measured in an artery, a diameter
stenosis of ≥70% in 1 angiographic view or ≥50% or higher in 2 orthogonal views assessed
by quantitative coronary angiography (QCA), as per the CE-MARC2 protocol [24]. For the
per-vessel analysis, an FFR threshold of ≤0.80 defined an arterywith obstructive epicardial
CAD.Microvascular dysfunctionwas defined as an abnormality in one ormore parameters
that reflect distinct properties of the microcirculation: increased microvascular resistance
(IMR ≥25)), impaired coronary vasodilator reserve (CFR b2.0), and impaired microvascu-
lar vasodilator capacity (RRR b2.0) [7,13,23].
2.5. Statistical analyses
The primary outcome was the prevalence of coronary microvascular dysfunction in
patients undergoing invasive management. The prevalence of microvascular dysfunction
in participants with NOCAD and obstructive epicardial CAD were prioritised secondary
outcomes. Results are expressed as mean± SD (range). Fisher's tests were used to com-
pare categorical variables and one-way ANOVAwas used to compare continuous variables
between patients with NOCAD and obstructive epicardial CAD. Variables associated
with epicardial CAD were tested for their ability to predict microvascular dysfunction in
univariate binary logistic regression analyses. Linear regression analysis was performed
to assess the relationship between parameters of microvascular function. A two-sided
value of p b 0.05 was considered significant. Statistical analyses were performed with
SPSS 15.0 (SPSS, Chicago, IL).
2.6. Sample size considerations
Pilot data indicated that FFR would be measured in approximately 10% (n= 120) of
the CE-MARC 2 participants undergoing invasive coronary angiography. This proportion
of participants undergoing FFR measurement and protocol-directed microvascular
function testing was anticipated to give clinically-meaningful results on the frequency of
microvascular dysfunction in symptomatic patients with angina, including those with
NOCAD and obstructive CAD.
3. Results
3.1. Characteristics of the participants undergoing invasive management
The flow of participants referred for invasive assessments in the trial
is shown in Fig. 1. Eighty-one patients had FFRmeasured in at least one
coronary artery (115 vessels). Parameters of microvascular function
were available in 85 coronary arteries from 63/81 (78%) patients. Logis-
tical reasons limited microvascular measurements in the remaining 18
patients.
The study population (n = 63) included 22, 18 and 23 patients
who had been randomised to CMR-guided, MPS-guided and NICE
guideline-based care, respectively. Their baseline clinical characteristics
are shown in Table 1. All patients had stable anginal symptoms, with
30 patients classified as having typical symptoms and 33 having atypical
symptoms.
3.2. Per-patient invasive coronary physiology analysis
3.2.1. Coronary physiology tests
Forty-five (71%) of the 63 patients had at least one abnormal param-
eter reflecting coronarymicrovascular dysfunction (Fig. 2). Patients with
more than one vessel undergoing microvascular function measurement
Fig. 1. CONSORT flow diagram. CONSORT flow diagram of patients enrolled in the CE-MARC 2 microvascular sub-study. Of 1202 patients enrolled into the CE-MARC 2 trial, 267 (22.2%)
underwent invasive coronary angiography and 119 (45%) of these patients had an indication for FFR measurement. Thirty-eight (32%) of these patients did not have FFR measured for
the following reasons: severe obstructive CAD, n = 15; urgent invasive management, n = 3; clinical and technical factors, n = 20. Eighty-one patients had FFR measured in at least
one coronary artery (115 vessels) and additional parameters of microvascular function were available for 63/81 (78%) patients in 85 vessels. Overall, 63 patients had coronary
microvascular function assessed, including 22, 18 and 23patients randomised to CMR-guided,MPS-guided andNICEmanagement-guided care, respectively. FFR= fractional flowreserve.
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function included in the analysis.
Twenty-five (40%) patients were classified as having NOCAD. Of
these patients, 17/25 (68%) had an abnormality in at least onemeasure-
ment of coronary microvascular function, and 5 (20%) patients had
concordantly abnormal IMR and CFR values.
Thirty-eight patients (60%) were classified as having obstructive
epicardial CAD. Of these patients, 15/38 (39%) had an abnormal IMR,and 12/38 (32%) had an abnormal RRR. A reduced CFR concordant
with the abnormal FFR, was present in 20/38 (53%) patients.3.2.2. Comparison of baseline clinical characteristics
The clinical characteristics of patients with obstructive and NOCAD
were similar, and the parameters of microvascular function were also
similar between the groups (Table 2).
Table 1
Baseline clinical characteristics of the study participants.
Variable n = 63
Age, years 58.5 ± 8.2
Male sex, n (%) 47 (75)
Height, m 1.71 ± 0.10
Weight, kg 83.4 ± 14.0
BMI, kg/m2 28.3 ± 3.8
Creatinine, μmol/l 79.4 ± 20.5
Gensini score 11.6 ± 10.3
Medical history: n (%)
Chest Pain
Typical 30 (48)
Atypical 33 (52)
Hypertension 32 (51)
Diabetes mellitus 10 (16)
Hypercholesterolemia 27 (43)
Current smoker 14 (22)
Ex-smoker 23 (37)
Never smoker 26 (41)
Family history of CAD 36 (57)
Cerebrovascular disease 1 (2)
Peripheral vascular disease 1 (2)
Baseline medical therapy: n (%)
Anti-platelet 46 (73)
Angiotensin converting enzyme inhibitor 17 (27)
Angiotensin receptor blocker 8 (13)
Statin 34 (54)
ß-blocker 37 (59)
Calcium channel blocker 12 (19)
Oral nitrate 6 (10)
Nicorandil 1 (2)
Oral hypo-glycemic agent 6 (10)
Insulin 2 (3)
Variables are presented as mean ± SD or n (%) as appropriate. BMI = body mass index,
GTN= glyceryl trinitrate, CAD= coronary artery disease.
Fig. 2. Abnormal invasive coronary microvascular function test results. Abnormal IMR, CFR and
microcirculatory resistance, CFR= coronary flow reserve, RRR= resistance reserve ratio.
Table 2
Comparison of baseline characteristics and coronary physiology in patients with NOCAD
and obstructive epicardial CAD.
Variable NOCAD (n = 25) Obstructive CAD (n = 38) p value
Baseline characteristics
Age, years 59.0 ± 8.5 58.2 ± 8.2 0.71
Male sex 16 (64%) 31 (82%) 0.15
Hypertension 13 (52%) 19 (50%) 0.99
Diabetes mellitus 4 (20%) 5 (13%) 0.50
Smoking history: 0.44
Current smoker 7 (28%) 7 (18%)
Ex-smoker 10 (40%) 13 (34%)
Never smoker 8 (32%) 18 (47%)
Hypercholesterolemia 11 (41%) 19 (48%) 0.63
Gensini score 13.2 ± 11.8 10.4 ± 9.1 0.31
Invasive coronary physiology results
FFR 0.91 ± 0.06 0.75 ± 0.14 b0.0001
IMR 25.6 ± 14.0 22.9 ± 13.1 0.44
RRR 2.4 ± 0.8 2.7 ± 1.2 0.34
CFR 2.2 ± 0.9 2.0 ± 0.9 0.56
Baseline resistance index 63.0 ± 49.6 61.0 ± 47.4 0.88
Variables aremean±SDandn (%)where appropriate. FFR= fractionalflow reserve, IMR=
index of microcirculatory resistance, CFR= coronary flow reserve, RRR= resistance reserve
ratio, RI= baseline resistance index. CAD=coronary artery disease.
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ated with obstructive epicardial CAD, females were more likely to
exhibit an abnormal IMR than males (OR 3.56 95% CI 1.09–11.61, p =
0.04). There were no statistically significant associates of abnormal
CFR or abnormal RRR. There was no statistically significant difference
in the proportion of patients with abnormal microvascular dysfunction
who underwent direct invasive coronary angiography (pre-test proba-
bility of CAD 61–90% randomised into the NICE guideline-based care)RRR on a per-patient and per-vessel basis. FFR= fractional flow reserve, IMR= index of
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(abnormal CFR p = 1.00, abnormal IMR p= 0.79, abnormal RRR p =
0.60). There was no statistically significant difference in the proportion
of patients with typical or atypical chest pain symptoms and either
abnormal CFR or abnormal IMR (p= 0.45 and p= 1.00, respectively).
In patients with atypical chest pain symptoms, there was a statistically
significant difference in the proportion with an abnormal compared to
normal RRR (26 vs. 7 patients, p = 0.10).
3.2.3. Non-invasive ischaemia testing
Forty of the 63patients had a non-invasive ischaemia test performed
prior to invasive angiography (comprised of patients randomised
to CMR-guided (n = 22), and MPS-guided (n = 18) care). Of these
40 patients, 31 (78%) demonstrated significant ischaemia, and 9 (22%)
patients had an inconclusive study. Fourteen (35%) patients had
NOCAD, of whom 9 (64%) had significant ischaemia and 5 (36%) an
inconclusive study. In total 10/14 (71%) patients with NOCAD had
abnormal invasive coronary microvascular function tests. There were
no differences in the non-invasive ischaemia test results (either signifi-
cant ischaemia or inconclusive study) and the number of patients with
microvascular dysfunction.
3.3. Per-vessel invasive coronary physiology analysis
Microvascular function was assessed in 85 coronary arteries (left
anterior descending artery n = 51 (60%), circumflex artery n = 12
(14%), right coronary artery n = 22 (26%)). 52/85 (61%) arteries had
an abnormality in at least one measurement of microvascular function
(Fig. 2).
Of the 85 arteries studied, 52 (61%)were classified as havingNOCAD
by FFR measurement. An abnormality in at least one measurement of
microvascular function occurred in 29/52 (56%) arteries (abnormal
IMR in 17/52 (33%), abnormal CFR in 19/52 (36%), and abnormal RRR
in 17/52 (33%)). 7/52 (14%) arteries had concordantly abnormal IMR
and CFR values.
In the 33/85 (39%) arteries with obstructive CAD, 23/33 (70%) arter-
ies had an abnormality in at least one measurement of microvascular
function microvascular dysfunction (abnormal IMR in 10/33 (30%)
arteries, and abnormal RRR in 9/33 (27%) arteries. A reduced CFR con-
cordant with the abnormal FFR, was present in 18/33 (55%) arteries,
and 5/33 (15%) arteries had concordantly abnormal IMR and CFR values.
There was a weak, positive correlation between CFR and FFR (r =
0.28, R2 = 0.08, p = 0.01). There was no correlation between RRR and
FFR (r = 0.06, R2 = 0.004, p = 0.56), or IMR and FFR (r = 0.03, R2 =
0.001, p = 0.81). There was a strong, positive correlation between
RRR and CFR (r= 0.91, R2 = 0.83, p b 0.001).
4. Discussion
We have shown that in an invasively managed population of
patients with stable symptoms prospectively enrolled in a contempo-
rary, multicentre, clinical trial, coronary microvascular dysfunction
was common. Specifically, 45 (71%) of 63 patients who had the relevant
tests had invasive evidence of coronary microvascular dysfunction,
and in patients with NOCAD a high proportion (17/25 (68%)) also had
invasive evidence of microvascular dysfunction. Secondly, microvascu-
lar dysfunction was also a frequent finding in patients with obstructive
epicardial CAD.
The distributions of CFR and IMR values indicate that these parame-
ters reflect distinct properties of coronary microvascular function and
are not interchangeable [12]. CFR reflects the vasodilator capacity of
the epicardial coronary artery and its subtended microvasculature,
whereas IMR is a directmeasure ofmicrovascular resistance. Our results
implicate abnormalities in microvascular function as a potential
explanation for abnormal false-positive non-invasive ischaemia test
results in symptomatic patients without obstructive epicardial CAD.For example, 14 (56%) of 25 patients with NOCAD underwent a non-
invasive ischaemia test prior to invasive coronary angiography, and
9/14 patients (64%) had evidence of clinically significant ischaemia. By
protocol, such results would be classified as false-positivewhen consid-
ered against invasive findings of NOCAD (i.e. FFR N0.80), leading to
false reassurance for patients and given the practice guideline recom-
mendations for microvascular angina [10], potentially sub-optimal
management. 71% of the patients with either positive or inconclusive
non-invasive stress tests had abnormal IMR, CFR or RRR, when assessed
invasively. This finding is consistent with prior literature, which de-
scribes subendocardial perfusion abnormalities in patients with micro-
vascular dysfunction [25]. In contrast to qualitative assessment, fully
quantitative stress perfusion CMR and positron emission tomography
(PET) allow for quantification of absolute myocardial blood flow
(in ml/g/min) and myocardial perfusion reserve (equivalent to CFR),
and these tests may be used to assess microcirculatory function follow-
ing exclusion of obstructive epicardial CAD [9,26,27]. An impairment in
vasodilator capacity during stress (e.g. secondary to diffuse atheroscle-
rosis) or increased microvascular resistance (e.g. secondary to micro-
vascular rarefaction or remodeling) may cause a supply-demand
mismatch in myocardial perfusion, leading to ischaemia and symptoms
in the absence of obstructive CAD or other relevant systemic health
problems (e.g. anaemia).
In CE-MARC 2, the primary endpoint was a protocol-defined unnec-
essary invasive coronary angiogram [15]. Of 139 patients with this
primary endpoint, 39 (28%) had a false-positive or inconclusive non-
invasive test (21 with CMR, 13 with MPS, and 5 undergoing non-
invasive imaging in the NICE guideline-based care group) [15]. Our
results indicate that if invasive parameters of microvascular function
were considered, the rate of false-positive tests results in the CE-
MARC 2 trial may have been lower, but rather than the selective
approach in our study, a future protocol should involve a systematic
measurement of coronary microvascular function in order to more
broadly assess disease prevalence in symptomatic patients.
Our data are consistent with other contemporary natural history
studies that demonstrate a high prevalence of microvascular dysfunc-
tion in patients with angina but angiographically unobstructed coro-
naries. Reis et al. in a sub-study of patients enrolled in the NHLBI-
sponsored Women's Ischemia Syndrome Evaluation (WISE) study,
assessed CFR with Doppler-derived flow velocity measurements in
159 females with chest pain and NOCAD on invasive angiography [28].
Seventy-four (47%) women had abnormal CFR (b2.5) consistent with
microvascular dysfunction. Lee et al. performed a comprehensive inva-
sive assessment of coronary function in 139 patients with angina and
NOCAD, and found that the majority of patients had at least one abnor-
mality to account for their symptoms (abnormal IMR (≥25) in 29 (21%)
patients, and abnormal coronary endothelial function in response to
acetylcholine testing in 61 (44%) patients) [13].
We found female sex to be the only predictor of abnormalmicrovas-
cular function (IMR ≥25). Recent studies have reported conflicting
associations between female sex and microvascular dysfunction. The
International Index of Microcirculatory Resistance Registry measured
IMR in 1096 patients (1452 vessels) undergoing elective invasive man-
agement. Female sex was a predictor of an elevated IMR, along with
prior myocardial infarction, right coronary artery, and obesity [29].
Kobayashi et al. measured IMR and CFR in the left anterior descending
artery of 147 patients with angiographically unobstructed coronaries.
There was no sex difference in IMR, but CFR was lower in females
thanmales predominantly due to shorter resting thermodilution transit
times in females, and female sex was an independent predictor of
reduced CFR [30]. However, Murthy et al. enrolled 1218 patients with
suspected angina referred for stress positron emission tomography
(PET) imaging. Patients were included if there was no evidence of ob-
structive epicardial CAD on PET imaging (assessed semi-quantitatively),
and using a CFR threshold b2.0 microvascular dysfunction was prevalent
in men and women (51% and 54% respectively) [9].
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with angina and obstructive epicardial CAD. The results implicate mi-
crovascular dysfunction as a potential explanation for recurrent angina
following myocardial revascularisation [31,32]. In a meta-analysis of
5 randomised trials (n = 5286) comparing PCI and optimal medical
therapy in patients with stable angina, 20.3% of patients undergoing
PCI had persistent angina [33]. Similarly, the ORBITA trial randomised
230 patients with angina and single vessel CAD to PCI or a sham proce-
dure [3]. There was no significant improvement in exercise time or an-
gina with PCI beyond the effect of the sham procedure. A number of
potential mechanisms for recurrent angina following revascularisation
of obstructive epicardial CAD (i.e. Type 3 coronary microvascular dys-
function) have been proposed, including endothelial dysfunction [34],
adverse microvascular remodeling distal to epicardial disease resulting
in impaired microvascular vasodilator capacity and increased microvas-
cular resistance [35], and anatomical and functional microvascular dys-
function due to distal embolisation of atherosclerotic material post-PCI
[36]. Our results implicatemicrovascular dysfunction as being a relevant,
potential explanation for the lack of benefit associated with PCI in some
patients.
In patients with atypical chest pain symptoms, there was a statisti-
cally significant difference in the proportion with an abnormal com-
pared to normal RRR (26 vs. 7 patients, p = 0.10). Given the small
patient numbers, and that this association was only demonstrated
with one parameter of microvascular function, the significance of this
result is uncertain and merits further study.
Our results also provide new insights into the possibility of false-
negative results with anatomical imaging methods, such as CTCA. In
SCOT-HEART, 4146 patients referred for investigation of known or
suspected angina were randomly assigned to standard care plus CTCA-
guided management (n = 2073) or standard care (n = 2073) alone
[37]. In a pre-specified analysis, symptoms and quality of life assessed
at baseline, 6 weeks and 6 months, improved less in patients assigned
to the CTCA-guided strategy as compared to standard care [38]. Whilst
several factors may be relevant, one potential explanation is that some
of the patients with NOCAD had microvascular or vasospastic angina
leading to false reassurance and suboptimal management. The natural
history of ischaemia in patients with NOCAD is being prospectively
assessed in the CIAO-ISCHEMIA (NCT02347215) sub-study of the
ISCHEMIA trial (NCT01471522). Our results may remind clinicians
that measurement of coronary microvascular function may be helpful
in patients with anginal symptoms and a negative invasive or non-
invasive coronary angiogram. The clinical utility of routine measure-
ment of coronary artery function in appropriately selected patients
is currently being assessed in the Coronary Microvascular Angina
(CorMicA) trial (NCT03193294).
We used a thermodilution technique for assessing microvascular
function as this method may be performed using the same coronary
guidewire as for guideline-directed FFR measurement. This technique
is straightforward and transferable to routine clinical practice [10].Mea-
surement of FFR, IMR, CFR, and RRR with one guidewire enables the
focused interrogation of epicardial andmicrovascular function. Doppler
flow assessment also enables measurement of microvascular function
(coronary flow velocity reserve (CFVR) and hyperaemic microvascular
resistance (hMR)), however this technique is less transferable to real-
world clinical practice.
4.1. Limitations
The prevalence of epicardial CAD in the CE-MARC 2 trial was lower
than estimated, with 119 (9.9%) patients having an indication for FFR
measurement. Only a sub-set (n= 67 (56%)) of the participants under-
going FFR measurement had microvascular function assessed, mainly
because of logistical reasons (e.g. lack of clinician experience with mi-
crovascular function testing). The interpretation of the results is limited
by the sample size for the sub-study as a proportion of the total CE-MARC 2 main trial cohort. Almost one third of the participants with a
protocol-directed indication for FFR lacked this measurement, which
in turn resulted in a lower proportion of participantswithmicrovascular
data than anticipated. Notwithstanding this point, our analysis includes
the largest number of participants with paired invasive measures of
microvascular function and non-invasive measures of ischaemia
derived in a multicentre setting. The core laboratory approach and
multicentre design mitigate against single centre effects e.g. positive
reporting bias, which we believe enhances the validity of our findings.
In the CE-MARC 2 trial, coronary angiography was invoked in patients
with evidence of non-invasive ischaemia, or patients with a high pre-
test probability of obstructive epicardial CAD in the NICE guideline-
directed care group. Potentially, patients with microvascular or vaso-
spastic angina may not have been referred for invasive angiography
as non-invasive CTCA and ischaemia testing may lack sensitivity for
coronary microvascular dysfunction.
The proportion of patients with abnormalities in coronary artery
function may be under-represented in our analysis because although
coronary microvascular resistance (IMR) and epicardial and microvas-
cular vasodilatory capacity (CFR and RRR) were systematically mea-
sured, assessment of coronary endothelial function and vasospasm
testing with acetylcholine was not part of the CE-MARC 2 protocol
[39]. Potentially, had these tests been performed, the prevalence of
clinically significant abnormalities of coronary artery function would
have been even higher [6,40].
5. Conclusions
Coronary microvascular dysfunction is a common finding in
invasively managed patients with angina in both those with NOCAD
and obstructive epicardial CAD. Our findings provide a potential expla-
nation for why PCI may not be beneficial, especially when performed
in patients who may have non-flow limiting CAD [3]. These results
may explain the occurrence of apparently false-positive non-invasive
ischaemia test results in some patients. Invasive assessment of micro-
vascular function may be informative and relevant for decision-
making in patients with both NOCAD and obstructive epicardial CAD.
Further research is required to assess the prevalence of coronary
microvascular dysfunction in patients with stable IHD, and ultimately
to determine whether routine measurement of microvascular function
leads to improved clinical care.
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